A partnership to advance NAMs

We are privileged to participate in the 3Rs Collaborative (3RsC) evidence-driven new alternative method (NAM) validation! The purpose is to evaluate liver MPS to differentiate DILI-positive and DILI-negative drugs for drug-induced liver injury (DILI) context of use (CoU) and regulatory review. Thank you to all collaborating stakeholders, including the 3RsC, the FDA, the Critical Path Institute (C-Path), the National Institute of Environmental Health Sciences (NIEHS), the NICEATM, end users and technology providers for this vital effort! Lena Biosciences is proud to be a part of it.​

June 25, 2025